The Pfizer Clinical Research Unit is conducting a clinical trial of a study drug for atopic dermatitis. Part 1 of this study will look at the effects of the study drug when given to healthy adults as a single injection beneath the skin (subcutaneous injection).
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin conditions. It causes a rash and itching and can negatively affect patients’ emotional well-being. There is no cure for AD and while available treatments may provide symptom relief, the community needs new long-term treatment options.
Learn how you can support patients as a healthy volunteer below.
Who may participate
All currently available medical treatments were first tested in a series of clinical trials, and clinical trials are made possible by participants.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-45 for males; 18-55 for females
Sex
All sexes
Referral bonus
Up to $200
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 21 consecutive overnights. On the morning after your admission, you will receive a single dose of the study drug or a placebo. Doses will be given as an injection under the skin (subcutaneous injection). You will continue to stay at the PCRU for monitoring and to collect information, such as how you feel and the amount of the study drug in your blood.
About a week after you are discharged (sent home) from the unit, you will return for a short visit to collect final information about the study drug and see how you are feeling. You are considered “on study” until this visit is completed and may not be able to participate in other trials.
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent document. You may request a copy of the ICD prior to your scheduled screening if you would like additional time to review it.
Required overnight stays
21 consecutive overnights
Long-term follow up
1 follow-up visit
How long is this study?
About 30 days
Compensation
Up to $9,950 upon completion of the study
The PCRU Loyalty Program has arrived!
Our new Loyalty Program offers unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.